-+ 0.00%
-+ 0.00%
-+ 0.00%

DNA X regains Nasdaq stockholders’ equity compliance after panel review

PUBT·08/31/2026 21:00:02
Listen to the news
DNA X regains Nasdaq stockholders’ equity compliance after panel review
  • Nasdaq hearings panel notified DNA X on Aug. 28, 2026 that it regained compliance with the $2.5 million stockholders’ equity rule.
  • Securities remain at risk of delisting if the company fails to stay compliant with all Nasdaq listing rules through Nov. 18, 2026.
  • Mandatory panel monitor runs until Aug. 28, 2027, tightening consequences for any renewed equity shortfall.
  • A repeat breach would trigger a delisting determination with no option to submit a compliance plan or receive extra time.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DNA X Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-040845), on August 31, 2026, and is solely responsible for the information contained therein.